Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2026)

Arcus Biosciences' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $209.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 8.85% year-over-year to $209.0 million in Q1 2026; TTM through Mar 2026 was $209.0 million, a 8.85% increase from a year earlier, with the FY2025 full-year figure at $231.0 million, up 2.21% from the prior year.
• Total Current Liabilities eased to $209.0 million in Q1 2026 per RCUS's latest filing, from $231.0 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $235.0 million in Q3 2025 and bottomed at $4.0 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $199.0 million (2024), against an average of $187.3 million.
• Across the five-year window, Total Current Liabilities sank 97.52% in 2023 and surged 5000.0% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $193.0 million in 2022, then fell by 4.66% to $184.0 million in 2023, then increased by 22.83% to $226.0 million in 2024, then gained by 2.21% to $231.0 million in 2025, then retreated by 9.52% to $209.0 million in 2026.
• Per Business Quant, the three latest RCUS Total Current Liabilities figures stand at $209.0 million (Q1 2026), $231.0 million (Q4 2025), and $235.0 million (Q3 2025).